NCT03787186

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection

A Phase 1, Open-label, Single-center Study to Investigate the Pharmacokinetics and Metabolism of GLPG1690 in Healthy Male Subjects Following Single Intravenous GLPG1690 Microtracer and Oral [14C]-GLPG1690 Administrations.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Galapagos NV · Industry
• Sex: Male
• Age: 30 Years – 64 Years
• Healthy volunteers: Accepted

Summary

The sponsor wants to investigate how well the test medicine is taken up by the body when given orally (by mouth) as a tablet or capsule and as a solution for infusion (into a vein). The capsule and the solution will be radiolabelled. 'Radiolabelled' means that the test medicine has a radioactive component which helps us to track where the test medicine is in the body.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	GLPG1690 film-coated tablets	a single oral dose of GLPG1690
DRUG	[14C]-GLPG1690 solution for infusion	a 15-minute IV infusion \[14C\]-GLPG1690
DRUG	[14C]-GLPG1690 capsules	single oral dose of \[14C\]-GLPG1690

Timeline

• Start date: 2018-11-09
• Primary completion: 2019-01-17
• Completion: 2019-01-17
• First posted: 2018-12-26
• Last updated: 2019-02-15

Locations

1 site across 1 country: United Kingdom